Firebrick Pharma Limited · ASX:FRE
Firebrick Pharma — Aussie Equities Day, Singapore 2026
15 slides from Firebrick Pharma's conference presentation, Oct 7, 2026
Slide 1: Firebrick Investor Update Presentation
7 October 2026 ASX Announcement For personal use only Firebrick Investor Update Presentation • Investor presentation with important details on the Company’s recently announced US retail plan for Nasodine Nasal Spray Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to release an inv
Slide 2: Aussie Equities Day, Singapore
rsonal use only AUSSIE EQUITIES DAY Singapore, 9 October 2026 Sponsored by Spark+ Peter Molloy Executive Chairman ASX: FRE firebrickpharma.com Authorised for release by the Executive Chairman of Firebrick Pharma Limited
Slide 3: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended to be relied upon as advice to investors or other persons. The information contained in this pre
Slide 4: Capital Structure Overview
Capital Structure Overview Financial Information (ASX: FRE) A$ rsonal use only Share price (52-week range} $0.024-0.070 Shares on Issue 285.2m Market cap (1 Oct 2026) $8.0m Cash balance (30 Jun 2026) $1.32m Quarterly burn (FY26 average) $0.65m Major shareholders (1 Oct 2026) P Molloy (CEO, Chairman)
Slide 5: Product Overview: Nasodine Nasal Spray
Product Overview: rsonal use only Nasodine® Nasal Spray (povidone-iodine 0.5%)
Slide 6: The rationale for a PVP-I nasal spray
rsonal use only The rationale for a PVP-I nasal spray • Povidone-iodine (PVP-I) is a well-established topical antiseptic (most widely marketed widely under BETADINE* brand) • PVP-I kills all respiratory viruses and has no resistance potential (unlike antivirals or vaccines) • Firebrick mission: crea
Slide 7: The world's first nasal spray that kills germs
rsonal use only • The world’s first nasal spray that kills germs, including all viruses and bacteria that cause nasal infections • Including all pandemic viruses tested • No evident potential for viral or bacterial resistance • A nasal sanitiser/antiseptic for: • Protection against airborne viruses
Slide 8: Backed by science and published clinical trials
Backed by science and published clinical trials (and not dependent on future clinical trial outcomes) rsonal use only • Backed by Science • 10 years of R&D • Published (open access) clinical trials • Granted international patents • R&D phase is behind us, now commercialising • The market need • Deve
Slide 9: The strategy in SE Asia
rsonal use only The strategy in SE Asia • Nasodine Nasal Spray launched Jun-24; first country in Asia; key test 2025 Population by Country in SE Asia market for Nasodine and regional hub for business development Singapore • Premium pricing in the region, but relatively small population and sales 300
Slide 10: Strategy in the US
Strategy in the US • Nasodine Nasal Spray can be marketed as a cosmetic ‘nasal cleanser’ without pre-approval by FDA rsonal use only • Nasodine has been available online only in the US since mid-2024 Through dedicated website and one online pharmacy partner • Nasodine.com has more than 1,000 custome
Slide 11: NACDS Annual Expo, Boston 15-17 August 2026
NACDS Annual Expo, Boston 15-17 August 2026 (NACDS = National Association of Chain Drugstores) • Annual meeting of retail buyers and decision-makers from rsonal use only • Independent drugstore groups • Wholesale banner groups • Major retail chains • Representing up to 50,000 drugstores across US •
Slide 12: USA Retail Launch Plan
Firebrick announcement 29 Sep 2026: USA Retail Launch Plan rsonal use only • Nasodine Nasal Spray to become available in US retail drugstores in 2027 • Three phase expansion process, starting with independent pharmacy groups • Potential for early orders from independent drugstore groups • US Commerc
Slide 13: What does this mean for Firebrick Pharma?
What does this mean for Firebrick Pharma? Potential to fully fund the company from US License Fees rsonal use only • Firebrick (ASX: FRE) receives license fees FRE License Fees on US Sales* from the US entity (Firebrick Pharma, Inc.): 25% • 12% royalty on sales % of Net Sales of US Licensee 20% 5% •
Slide 14: Investor summary
Investor summary rsonal use only • US retail opportunity is a ‘game- changer’ for Firebrick • Combined with Asian license fees, the US could significantly accelerate positive cash flows for FRE • US market will become a focus for Firebrick and source for significant future news flow
Slide 15: For more information
rsonal use only For more information: www.firebrickpharma.com ASX: FRE The world needs
Firebrick Pharma — Aussie Equities Day, Singapore 2026 on 6ix